In Vivo Involvement of the Cholinergic and Dopaminergic Systems in the Pathophysiology of Apathy.

Phase 3

• Conditions: Apathy
• Interventions: Drug: Positron Emission Tomography (PET) with [18F]-FDOPA; Drug: Positron Emission Tomography (PET) with [18F]-FEOBV; Device: Magnetic Resonnance Imaging (MRI); Other: Neuropsychological evaluation

• Registration Number: NCT03998852
• Lead Sponsor: University Hospital, Bordeaux

Brief Summary

Apathy is a neurocognitive syndrome characterized by reduced goal-directed behaviors, contributing to decreased patient and caregiver quality of life. Apathy pathophysiology involves disruption of cortico-striato-thalamo-cortical loops, modulated by several neurotransmitter systems including dopamine and acetylcholine, thus complexifying pharmacological management. Post-stroke apathy (PSA) can provide a proper in vivo model to study the underlying neurochemical substrates of apathy as a syndrome. The present project aims to provide a better characterization of the cholinergic and dopaminergic functioning in apathy as a syndrome.

In order to precise the respective alterations of these two systems, investigators will use a positron emission tomography (PET) molecular imaging of dopaminergic (with \[18F\]-FDOPA, a marker of the decarboxylating enzyme of dopamine) and - for the first time in apathetic patients - cholinergic (with \[18F\]-FEOBV, a marker of the vesicular acetylcholine transporter) transmissions in 15 apathetic and 15 unapathetic patients 3 months after stroke, without overlapping depression. This dual imaging study may provide help in guiding therapeutic management of PSA. The functional network analysis allowed by functional MRI is crucial to complement regional neurotransmitter deficits observed with PET. Altogether, a multimodal approach in apathy, combining PET and MRI, can allow identifying which circuits of the cortico-striato-thalamo-cortical loops are disrupted and how these circuits are modulated by other neurotransmitters.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-06-20
• Study First Submitted QC: 2019-06-24
• Study First Posted: 2019-06-26
• Study Start: 2021-04-13
• Status Verified: 2021-05
• Last Update Submitted: 2021-05-28
• Last Update Posted: 2021-06-01
• Primary Completion: 2022-04-13
• Study Completion: 2022-05-13

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Patient of legal age and younger than 75 years
• Patient with a Rankin score less then or equal to 2 and with or without apathy, demonstrated by AI scales at 3 months after stroke (apathetic patient = AI scale score > 2)
• Affiliate or beneficiary of a social security scheme
• Subjects (female study subjects and female partners of male participants) using highly effective contraceptive methods (intra-uterine device, progestin or estrogen-progestin contraceptive, sterilization)
• Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research)

Exclusion Criteria

• Patients over 75 years old
• Taking of any pharmacological treatment likely to affect cholinergic systems at the time of PET-scan: Amitriptyline, Atropine, Brompheniramine, Chlorphenamine, Chlorpromazine, Clomipramine, Clozapine, Dimenhydrinate, Diphenhydramine, Doxepine, Hyoscyamine, Imipramine, Meclozine, Nortriptyline, Oxybutynine, Promethazine, Scopolamine, Trimipramine, Hydroxyzine.
• Taking of any pharmacological treatment likely to affect dopaminergic systems at the time of PET-scan: glucagon, haloperidol, reserpin
• Taking of any selective serotonine reuptake inhibitors treatment
• White matter T2 hyperintense lesions (Fazekas score > 3)
• NYHA Class III to IV Heart Failure Patient
• Patients with allergy or conter-indication to entacapone
• Subjects with positive pregnancy test (BHCG dosage and Urine dipstick), and/or currently breast-feeding
• Patients unable to come back to hospital for at least 2-follow-up visits
• Patient with a chronic neurological disorder or severe psychiatric disorder
• Patient with cognitive impairment (MoCA<24) and depression (CES-D score > 17 for men and >23 for women)
• Patient presenting a counter-indication for MRI
• Patient presenting a counter-indication for TEP with [18F]-FEOBV or [18F]-FDOPA (known allergy)
• Patient who underwent a PET examination in the previous month
• Patient with state of health not allowing a displacement in the department of imaging of the CHU: bedridden state, state of health very deteriorated
• Patient deprived of liberty by judicial or administrative decision
• Patient under legal protection or unable to express its own consent
• Subject within exclusion period from another clinical trial

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Molecular imaging	Magnetic Resonnance Imaging (MRI)	Positron Emission Tomography (PET) molecular imaging of dopaminergic and cholinergic systems using two radiotracers
Molecular imaging	Neuropsychological evaluation	Positron Emission Tomography (PET) molecular imaging of dopaminergic and cholinergic systems using two radiotracers
Molecular imaging	Positron Emission Tomography (PET) with [18F]-FDOPA	Positron Emission Tomography (PET) molecular imaging of dopaminergic and cholinergic systems using two radiotracers
Molecular imaging	Positron Emission Tomography (PET) with [18F]-FEOBV	Positron Emission Tomography (PET) molecular imaging of dopaminergic and cholinergic systems using two radiotracers

Primary Outcome Measures

Name	Time	Method
[18F]-FEOBV SUVr	First visit (Day 0)	Standardized uptake value for the \[18F\]-FEOBV radiotracer
[18F]-FDOPA SUVr	Between 7 and 30 days after first visit	Standardized uptake value for the \[18F\]-FDOPA radiotracer

Secondary Outcome Measures

Name	Time	Method
Center of Epidemiology Studies Depression Scale (CES-D) Score	First visit (Day 0)	Center of Epidemiology Studies Depression Scale (CES-D); The frequency of occurrence of symptoms is measured with a 4 points scale : o = Never; 1. = Occasionally; 2. = Quite often; 3. = Frequently The total score is between 0 and 60. Highest scores correspond to the presence of a more severe depressive symptomatology Depressive patients = score \> 17 for men and \>23 for women
Apathy Inventory Score	First visit (Day 0)	Apathy score from 0 to 36. Apathetic patient = score \>2
Mean diffusivity	First visit (Day 0)	Mean diffusivity measured with structural MRI
Fractional anisotropy	First visit (Day 0)	Fractional anisotropy measured with structural MRI
Cerebral blood flow maps	First visit (Day 0)	Cerebral blood flow maps provided by arterial spin labeling sequences
Beck Anxiety Inventory (BAI) Score	First visit (Day 0)	Beck Anxiety Inventory (BAI). Score from . Anxiety = score \> 22
Lille Apathy Rating Scale (LARS) Score	First visit (Day 0)	Complementary assessment of apathy. Score from - 36 to 36. Score \< - 22 : no apathy; * 21 to -17 : apathy tendancy; * 16 to -10 : moderate apathy; * 9 to 36 : severe apathy
Multidimensional Fatigue Inventory (MFI) Score	First visit (Day 0)	The MFI contains 20 items classified into four dimensions : general fatigue, mental fatigue, reduced activities and motivation. The statements are rated on a 5-point Likert scale (from "Yes, that is true" to "No, that is not true") representing the patient's current feeling. Low MFI scores reflect a higher degree of fatigue.

Trial Locations

Locations (1)

Bordeaux University Hospital; 🇫🇷 Bordeaux, France